XRAY

Dentsply Sirona

$9.16

-0.87%
Nov 13, 2026
Bobby Quantitative Model
Dentsply Sirona is one of the world's largest manufacturers of dental equipment, consumables, and laboratory products, formed by the 2016 merger of Dentsply International and Sirona Dental Systems; its portfolio spans CAD/CAM and imaging technology, orthodontic and endodontic products, implants, and infection-prevention consumables, sold roughly two-thirds through third-party distributors and the remainder direct to labs, dental offices, and consumers. As a scaled incumbent in a consolidated dental oligopoly alongside Envista and Align, the company's identity rests on its unmatched breadth of chairside-to-lab workflow solutions rather than on any single high-growth franchise. The current investor narrative is dominated by a credibility-challenged turnaround: a Q3 2026 earnings miss with weakness concentrated in orthodontics and implants, persistent margin compression, soft underlying dental demand, and a deeply depressed share price that has left the stock searching for a floor. Management's ability to stabilize revenue and defend margins against distributor destocking and macro-sensitive elective procedures is the central debate, with the market increasingly pricing skepticism rather than recovery.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
West Pharmaceutical Services (United States)

West Pharmaceutical Services (United States)

WST

Analysis

BobbyInvestment Opinion: Should I buy XRAY Today?

Rating: Hold (with a speculative-value caveat). The core thesis is that XRAY is a deeply discounted but unproven turnaround: at $9.46 it trades at 0.62x sales and roughly 5.8x the $1.64 consensus forward EPS, yet revenue is shrinking 7.52% YoY, Q3 2026 produced a -$2 million net loss, and free cash flow is effectively zero — so the cheap multiple is only real if the estimate holds. The 11-analyst coverage skews Neutral/Market Perform (Mizuho, Leerink, Piper Sandler, BMO) with Barclays Underweight and only UBS and Barrington constructive; with no explicit price targets in the dataset, the qualitative consensus signal is neutral-to-bearish and offers no upgrade catalyst.

Supporting evidence is genuinely mixed. On the positive side, gross margin of 52.99% in Q3 2026 recovered from 48.52% in Q1 and sits near Q2's 54.90%, showing pricing power; the 5.62% dividend yield provides meaningful carry; the stock is 13.6% above its $8.42 October low and posted a +10.77% one-month return versus SPY's -4.99% (+15.76pp relative strength); and 0.62x PS is at or below the bottom of a historical band that ran 2.1-2.6x in recent quarters and 7-11x in 2021-2022. Against that, revenue fell from $904 million to $836 million YoY, operating margin compressed to 4.43% from 9.13% in Q2, debt-to-equity is 1.84x against only $195 million of cash, ROE is -44.63%, and TTM free cash flow is just $103 million — the company is not self-funding.

The biggest risks that could invalidate even a Hold are: (1) further estimate cuts to the $1.64 EPS, which would make the 5.8x multiple look expensive on revised numbers; (2) continued orthodontic and implant weakness driving another revenue leg down; and (3) a breakdown below the $8.42-$8.56 support triggering momentum selling. This Hold would upgrade to Buy if revenue stabilizes (flat to positive YoY) and free cash flow turns sustainably positive, or if the stock retests the low-$8s with margin stabilization; it would downgrade to Sell if Q4 guidance is cut, EPS estimates fall below $1.50, or the $8.42 low breaks decisively. Valuation verdict: undervalued relative to its own history and scaled medical-supply peers on sales, but fairly-to-fully valued on the risk-adjusted forward earnings that the market is explicitly discounting — a value trap until the fundamental trend inflects.

Sign up to view all

XRAY 12-Month Price Forecast

XRAY presents a classic deep-value-versus-value-trap tension: the 0.62x sales and ~5.8x forward EPS multiples are at multi-year troughs, and the 5.62% dividend yield plus a +15.76pp one-month relative-strength bounce off the $8.42 low suggest a floor may be forming. But the fundamentals do not yet support a re-rating — revenue is shrinking 7.52% YoY, Q3 2026 posted a net loss, free cash flow is effectively zero, and leverage of 1.84x debt-to-equity amplifies earnings volatility. The Street's tight $1.60-$1.66 EPS range and Neutral-to-Underweight skew indicate high conviction in a low-growth, margin-constrained outcome rather than a rebound, and the absence of upgrades despite a 14.16% one-year decline confirms no near-term catalyst. I would upgrade to bullish if revenue stabilizes and free cash flow turns sustainably positive, or if the stock retests the low-$8s with gross margin holding above 52%; I would downgrade to bearish if Q4 guidance is cut or the $8.42 support breaks decisively.

Historical Price
Current Price $9.16
Average Target $9.16
High Target $10.53
Low Target $7.79

Wall Street consensus

Coverage is moderate at 11 analysts, and the sentiment is decidedly cautious: the visible institutional ratings skew heavily toward Neutral and Market Perform (Mizuho, Leerink, Piper Sandler, BMO), with Barclays maintaining an Underweight and only UBS (Buy) and Barrington Research (Outperform) on the constructive side. Consensus estimated EPS of $1.64 (range $1.60–$1.66) and estimated revenue of $3.76 billion (range $3.70–$3.80 billion) imply analysts expect only modest stabilization, not a sharp rebound. Against the $9.46 price, the $1.64 consensus EPS implies a forward multiple near 5.8x, which suggests the market is discounting the estimates themselves — a bearish tell. The tight EPS range ($1.60–$1.66, a spread of under 4%) signals high conviction in a low-growth, margin-constrained outcome rather than divergent bull/bear scenarios, while the persistent Underweight and Neutral reiterations through October 2026 indicate analysts are holding fire rather than upgrading into the weakness. With no explicit price targets provided in the dataset, implied upside cannot be calculated precisely; the qualitative signal is that consensus leans neutral-to-bearish, and the absence of recent upgrades despite a 14% one-year decline implies the Street sees no near-term catalyst to re-rate the shares.

Drowning in data?

Find the real signal!

Bulls vs Bears: XRAY Investment Factors

The bear case currently holds stronger evidence: revenue is contracting 7.52% YoY, the company posted a Q3 net loss, ROE is -44.63%, and free cash flow is effectively zero, while the Street's 11 analysts lean Neutral-to-Underweight with a tight, low-growth EPS consensus. The bull case rests almost entirely on valuation — 0.62x sales and ~5.8x forward EPS are at or below historical troughs — plus a 5.6% dividend yield and a nascent one-month bounce off the $8.42 low. The single most important tension is whether the ~$1.64 forward EPS is real: the market is pricing roughly 5.8x that number, so if margins stabilize and the estimate holds, the multiple can re-rate sharply, but if orthodontics and implant weakness pushes estimates lower, the 'cheap' multiple is an illusion. Until revenue stops shrinking and free cash flow turns positive, the value case is a falling-knife bet on a credibility-challenged turnaround.

Bullish

  • Deep value on price-to-sales: At $9.46 the stock trades at just 0.62x sales, versus a historical band of roughly 2.1-2.6x in recent quarters and 7-11x in 2021-2022. That is at or below the bottom of its own multi-year range, implying the market has already priced in substantial structural deterioration.
  • Forward EPS implies ~5.8x multiple: Consensus forward EPS of $1.64 against the $9.46 price yields a forward multiple near 5.8x, a level that discounts the estimates themselves. If Dentsply merely delivers the consensus number, the multiple has room to normalize toward medical-supply peer levels.
  • Gross margin holding near 53%: Q3 2026 gross margin of 52.99% was up from 48.52% in Q1 2026 and only modestly below Q2's 54.90%, showing pricing power and mix discipline in the core franchise even as revenue fell 7.52% YoY. A 50%+ gross margin is the raw material for margin recovery if volumes stabilize.
  • One-month relative strength +15.76pp: XRAY's +10.77% one-month return versus SPY's -4.99% produced a 15.76 percentage-point relative-strength spread, evidence that buyers stepped in aggressively at the $8.42 October low. The stock is 13.6% above that 52-week low, suggesting a floor may be forming.

Bearish

  • Revenue contracting 7.52% YoY: Q3 2026 revenue of $836 million fell 7.52% from $904 million a year earlier and declined sequentially from $898 million in Q2 and $880 million in Q1. A shrinking top line in what should be a resilient consumables annuity undermines the entire recovery thesis.
  • Losses and negative ROE of -44.63%: Q3 2026 net income was -$2 million (EPS -$0.01) and trailing EPS is -$0.26, with ROE of -44.63% and a TTM net margin of -16.25%. The company is destroying rather than generating shareholder value, and the trailing PE of -3.81x and EV/EBITDA of -96x leave no clean earnings anchor.
  • Leverage with thin cash cushion: Debt-to-equity of 1.84x against only $195 million of cash and a current ratio of 1.51 leaves limited flexibility. Q3 interest expense of $25 million plus a $29 million tax charge overwhelmed $37 million of operating income, showing how leverage amplifies earnings volatility.
  • Zero quarterly free cash flow: Q3 operating cash flow of $32 million was fully consumed by $32 million of capex, and TTM free cash flow is only $103 million. The company is not self-funding and depends on refinancing and cost cuts rather than organic cash generation.

XRAY Technical Analysis

The prevailing trend is a sustained, multi-leg downtrend interrupted by a violent but failed summer rally. XRAY is down 14.16% over the past year and 16.06% year-to-date, and at $9.46 it sits just 13.6% above its 52-week low of roughly $8.42 (set October 19, 2026) and 32.6% below the 52-week high of $14.27 reached August 4 — effectively trading in the bottom third of its annual range. That positioning signals a broken chart and a falling-knife profile rather than a value floor, with the stock having surrendered the entire July–August advance and a maximum drawdown of -42.64% underscoring how punishing the decline has been for holders. Recent momentum is bifurcated and unstable: the 1-month change of +10.77% looks constructive and produced a striking +15.76 percentage-point relative-strength spread versus SPY's -4.99%, but the 3-month change of -21.95% and 6-month change of -14.0% reveal that the one-month bounce is a counter-trend rally off oversold levels rather than a trend reversal. The most recent session is a warning — a -6.24% single-day drop from $10.09 to $9.46 on elevated volume of 10.28 million shares — suggesting the post-earnings rebound is being sold into and that the 1-month strength is decelerating sharply. Key levels are well defined: support sits at the $8.42–$8.56 October low, and a breakdown there would confirm a fresh leg lower and likely trigger momentum-driven selling; resistance is the $10.65–$11.00 zone (the November 4 spike high and the September breakdown shelf), with a decisive reclaim needed to neutralize the bearish structure. With no beta provided, the -42.64% max drawdown and 6%+ single-day moves imply volatility well in excess of the broad market, warranting smaller position sizing and wider stops for anyone attempting to catch the turn.

Beta

—

—

Max Drawdown

-42.6%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

-16.3%

Cumulative gain past year

PeriodXRAY ReturnS&P 500
1m+8.5%-2.3%
3m-21.0%-2.8%
6m-9.0%+2.1%
1y-16.3%+12.3%
ytd-18.7%+10.6%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

XRAY Fundamental Analysis

The revenue trajectory is deteriorating, not stabilizing. Q3 2026 revenue of $836 million fell 7.52% year-over-year, extending a sequence of declines from $898 million in Q2 2026 and $880 million in Q1 2026, and down from $904 million in the year-ago Q3 2025. Segment data shows Technologies and Equipment at $548 million and Consumables at $430 million, with the Q3 miss explicitly attributed to weakness in orthodontics and implants — the higher-growth, higher-multiple franchises — meaning the mix is shifting toward slower, more commoditized categories just as the top line contracts. For a company with roughly $3.5 billion in annualized revenue, a mid-single-digit organic decline is a serious erosion of the investment case, since dental consumables should be a low-growth-but-resilient annuity rather than a shrinking one. Profitability is thin and volatile. Q3 2026 net income was just -$2 million (EPS -$0.01) on a 52.99% gross margin, with operating income of $37 million (4.43% operating margin) and a net margin of -0.24%; the trailing-twelve-month picture is worse, with a -16.25% net margin and -$0.26 EPS. Gross margin has oscillated from 48.52% in Q1 2026 to 54.90% in Q2 to 52.99% in Q3, while operating margin compressed from 9.13% to 4.43% quarter-over-quarter as $25 million of interest expense and a $29 million tax charge overwhelmed a modest $37 million operating profit — evidence that leverage and a heavy fixed cost base are amplifying earnings volatility. The balance sheet carries real risk: debt-to-equity of 1.84x, a current ratio of 1.51, and cash of only $195 million against meaningful debt service leave limited cushion. Free cash flow is weak at $103 million TTM, Q3 operating cash flow was just $32 million against $32 million of capex (zero quarterly FCF), and ROE of -44.63% reflects both losses and a leveraged equity base; the company is not self-funding growth comfortably and remains dependent on refinancing and cost discipline rather than organic cash generation.

Quarterly Revenue

$836000000.0B

2026-09

Revenue YoY Growth

-7.5%

YoY Comparison

Gross Margin

53.0%

Latest Quarter

Free Cash Flow

$103000000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Technologies And Equipment
Consumables Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is XRAY Overvalued?

Because trailing net income is negative (EPS -$0.26, trailing PE of -3.81x), the PE ratio is not meaningful and I am leading with the price-to-sales ratio of 0.62x, supplemented by the 1.70x price-to-book and 9.70x price-to-cash-flow. The forward PE of 0.12x is a data artifact that should be disregarded; the more useful signal is the consensus forward EPS of $1.64 against a $9.46 price, implying roughly 5.8x forward earnings — a multiple that prices in severe skepticism about the durability of that estimate. The gap between a negative trailing earnings base and a positive forward estimate implies the market expects a sharp earnings recovery that has not yet appeared in reported results. On a relative basis, a 0.62x PS ratio is far below the 2–4x range the stock historically commanded and below what scaled medical-supply peers typically trade at, a discount that reflects genuine fundamental deterioration rather than a simple mispricing. The 1.70x P/B is near the low end of the stock's own multi-year band, which ranged from roughly 1.3x to 2.4x, and the historical PS ratio has collapsed from 7–11x in 2021–2022 to roughly 2.1–2.6x in recent quarters — meaning the current 0.62x reading is at or below the bottom of its historical range. That compression can be read two ways: as a deep-value opportunity if margins stabilize, or as the market correctly discounting structural margin erosion, a leveraged balance sheet, and negative ROE of -44.63%; with EV/EBITDA at -96x due to depressed EBITDA, the valuation offers no clean earnings-based anchor.

PE

-3.8x

Latest Quarter

vs. Historical

Low-End

5-Year PE Range 15x~38x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

-96.1x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are acute. Revenue fell 7.52% YoY to $836 million in Q3 2026, the third consecutive sequential decline, with the miss concentrated in higher-margin orthodontics and implants, shifting mix toward slower consumables. Operating margin compressed to 4.43% from 9.13% in Q2 as $25 million of interest expense and a $29 million tax charge overwhelmed $37 million of operating income, while debt-to-equity of 1.84x, only $195 million of cash, and a current ratio of 1.51 leave a thin cushion. Free cash flow is the sharpest warning: Q3 operating cash flow of $32 million was fully absorbed by $32 million of capex, leaving zero quarterly FCF and just $103 million TTM, so the company is not self-funding and depends on refinancing and cost discipline.

Market and competitive risks compound the fundamental pressure. At 0.62x sales and ~5.8x forward EPS, the stock is optically cheap, but that discount reflects genuine deterioration rather than mispricing, and the negative trailing PE (-3.81x) and EV/EBITDA (-96x) offer no earnings anchor — meaning any further estimate cuts could trigger another leg of multiple compression. Dentsply competes in a consolidated dental oligopoly against Envista and Align, and the Zacks commentary explicitly notes peers like NVST showing stronger momentum, raising share-loss risk in exactly the categories (orthodontics, implants) where Dentsply is already weak. With no beta provided, the -42.64% max drawdown and 6%+ single-day moves (the most recent session fell 6.24% on 10.28 million shares) imply volatility well in excess of the market, and the 14.16% one-year decline alongside a -23.75pp relative-strength gap versus SPY signals persistent sector-rotation headwinds.

The worst-case scenario is a self-reinforcing downgrade cycle: orthodontic and implant weakness persists into Q4, management guides down, the $1.64 consensus EPS is cut, and the 'cheap' 5.8x multiple is revealed as expensive on revised numbers, forcing another de-rating. A breakdown below the $8.42-$8.56 October support would confirm a fresh leg lower and likely trigger momentum-driven selling. From the current $9.46, a retest of the 52-week low of $8.42 implies roughly -11%, and a full re-run of the -42.64% max drawdown from the $14.27 August high would imply a price near $8.19, or about -13% from here; a more severe scenario where estimates reset lower could push the stock into the high-$7s, a -15% to -20% downside. Position sizing should reflect that this is a high-volatility, broken-chart name where the floor is unproven.

FAQ

The most severe risk is fundamental deterioration: revenue fell 7.52% YoY to $836 million in Q3 2026 with the miss concentrated in higher-margin orthodontics and implants, and if that persists into Q4 the $1.64 consensus EPS gets cut, instantly making the 5.8x multiple look expensive. Second is balance-sheet and cash-flow stress — debt-to-equity of 1.84x against only $195 million of cash, a current ratio of 1.51, and zero quarterly free cash flow ($32 million operating cash flow fully absorbed by $32 million capex) leave little room if refinancing conditions tighten or the dividend (negative payout ratio) comes under review. Third is competitive and mix risk: Dentsply competes against Envista and Align in a consolidated dental oligopoly, and peers like NVST are showing stronger momentum in exactly the categories where Dentsply is weakest, raising share-loss risk. Fourth is technical/momentum risk — the stock is down 14.16% over one year with a -23.75pp relative-strength gap versus SPY, and a decisive break below the $8.42-$8.56 support could trigger another leg of selling. Ranked by severity: estimate cuts first, cash-flow/leverage second, competitive share loss third, technical breakdown fourth.

The 12-month outlook is split into three scenarios. The base case (55% probability) targets $8.42-$10.65 — a range-bound grind between the October low and the November 4 spike high — assuming revenue declines moderate to low-single-digit, gross margin holds in the 50-53% band, and the $1.64 consensus EPS is met without a cut. The bear case (25%) targets $7.00-$8.42, driven by a Q4 2026 miss that forces EPS estimates below $1.50, a decisive break of the $8.42 support, and accelerating distributor destocking. The bull case (20%) targets $12.50-$14.27, requiring orthodontic and implant weakness to bottom in Q4 2026, management to guide flat-to-positive 2027 revenue, free cash flow to turn positive, and the multiple to re-rate toward 8-9x on intact estimates. The base case is most likely because the 5.62% dividend yield and 0.62x sales floor limit downside while the discounted multiple caps upside; the key assumption is that the $1.64 EPS proves durable. Note that probabilities sum to 100% and the wide bull-bear spread reflects genuine uncertainty about the turnaround.

On sales, XRAY looks deeply undervalued: the 0.62x PS ratio sits at or below the bottom of a historical band that ran roughly 2.1-2.6x in recent quarters and 7-11x in 2021-2022, and the 1.70x price-to-book is near the low end of its 1.3x-2.4x multi-year range. The 9.70x price-to-cash-flow is also modest. However, trailing earnings are negative (EPS -$0.26, trailing PE -3.81x, EV/EBITDA -96x), so those multiples offer no clean earnings anchor, and the forward PE of 0.12x is a data artifact that should be ignored — the meaningful figure is ~5.8x the $1.64 consensus forward EPS. That forward multiple is itself a warning: the market is explicitly discounting the estimate rather than paying for it, which is what a stock does when investors doubt the numbers. So the honest verdict is undervalued relative to its own history and scaled medical-supply peers on sales, but fairly-to-fully valued on risk-adjusted forward earnings — a value trap until the fundamental trend inflects. The market is pricing structural margin erosion and a leveraged balance sheet, not a temporary stumble.

From a pure risk/reward standpoint, XRAY is a speculative value bet rather than a clean buy. The upside case is real: at 0.62x sales and ~5.8x the $1.64 consensus EPS, a re-rating toward 8-9x on intact estimates could lift shares toward the $12.50-$14.27 range, implying 32%-51% upside from $9.46, and the 5.62% dividend yield pays you to wait. But the downside is equally concrete — a retest of the $8.42 52-week low is roughly -11%, and a full re-run of the -42.64% max drawdown implies about -13% to $8.19, with a deeper estimate reset pushing into the high-$7s. The deciding factor is whether the $1.64 EPS holds; revenue is still shrinking 7.52% YoY and free cash flow is zero, so the 'cheap' multiple is only real if margins stabilize. It is a reasonable buy only for risk-tolerant investors with a 2-3 year horizon who can stomach another 15-20% drawdown and size the position small; it is not a good buy for conservative or income-focused portfolios until revenue and cash flow inflect.

XRAY is better suited to a patient, long-horizon value approach than to short-term trading, but only for investors who can tolerate volatility. The stock has no beta in the dataset, yet the -42.64% max drawdown and 6%+ single-day moves (the most recent session fell 6.24% on 10.28 million shares) imply volatility well above the broad market, making it a poor fit for tight-stop traders. The 5.62% dividend yield rewards holding through the turnaround, but the negative payout ratio means the dividend is not yet covered by GAAP earnings, so income reliability is not guaranteed. Earnings visibility is low — analysts cluster in a tight $1.60-$1.66 EPS range but the company has posted net losses in three of the last four reported quarters. A concrete suggested minimum holding period is 18-24 months, long enough to see whether Q4 2026 and 2027 guidance confirm revenue stabilization and positive free cash flow; shorter horizons are essentially bets on the technical bounce off $8.42 holding, which is a trade, not an investment.